Skip to main navigation
Bolt
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Platforms
    • Publications
  • Pipeline
    • BDC-1001
    • BDC-3042
  • Patients
  • Careers
  • Investors & Media
    • Overview
    • News & Events
      • News Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
      • Governance Highlights
      • Management Team
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • Resources
      • Email Alerts
      • Contact IR
  • Menu Menu

Event Details

American Association for Cancer Research (AACR) Annual Meeting 2021

April 10, 2021

Supporting Materials

Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with anti-PD1 antibody in patients (pts) with HER2-expressing advanced solid tumors 2.5 MB
Targeting HERS2 with Immune-Stimulating Antibody Conjugates (ISACS) 1.6 MB
Bolt Biotherapeutics, Inc

900 Chesapeake Drive
Redwood City, CA 94063
Phone: 650.665.9295
info@boltbio.com

 

 
© 2023 - Bolt Biotherapeutics - All rights reserved.
  • Terms of Use
  • Privacy Policy
Scroll to top